Rezaei Mansour, Khoshay Ahmad, Amirifard Nasrin, Goli Ali, Abdi Alireza
Department of Biostatistics, Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Nursing, School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran.
J Skin Cancer. 2021 Jun 16;2021:5575688. doi: 10.1155/2021/5575688. eCollection 2021.
Radiotherapy in breast cancer patients is associated with acute and delayed side effects. This study aimed to compare the effect of alpha and hydrocortisone 1% (H1%) ointments on prevention of acute skin complications due to radiotherapy in breast cancer patients.
This clinical trial was conducted on 86 patients with breast cancer in the radiotherapy center of Imam Reza Hospital of Kermanshah, Iran. Using the records, the patients were selected and randomly divided into alpha and H1% groups after obtaining informed consent. The severity of dermatitis, complications, and patient complaints during treatment were evaluated weekly for up to 6 weeks by RTOG criteria. Data were analyzed using SPSS-16 software.
At the end of the third, fourth, fifth, and sixth weeks, 10 (11.7%), 25 (29.1%), 53 (61.6%), and 28 (32.6%) patients had skin complications, respectively. In weeks 5 and 6 in the H1 group, the incidence of complications was higher ( = 0.001). The frequency of pain and burning complaints at the end of the third, fourth, fifth, and sixth weeks was 15 (17.4%), 37 (43.0%), 52 (60.5%), and 1(1.2%), respectively. Pain and burning intensity in the fourth and fifth weeks in the H1 group was lower than alpha ( = 0010). Complaints of skin itching at the end of the third, fourth, and fifth weeks were 16 (18.6%), 25 (29.1%), and 28 (32.6), respectively. This complication was lower in the H1% group during these weeks ( < 0.05).
Alpha ointment is more effective than H1% in relieving pain and burning, preventing complications except itching. It seems using an alpha ointment or combining it with H1% is an appropriate strategy to reduce the rate of injuries and skin complications of radiotherapy.
乳腺癌患者放疗会产生急性和迟发性副作用。本研究旨在比较α软膏和1%氢化可的松(H1%)软膏对预防乳腺癌患者放疗所致急性皮肤并发症的效果。
本临床试验在伊朗克尔曼沙赫伊玛目礼萨医院放疗中心对86例乳腺癌患者进行。通过查阅记录选取患者,获得知情同意后将其随机分为α组和H1%组。采用放射肿瘤学协作组(RTOG)标准,每周评估一次治疗期间的皮炎严重程度、并发症及患者主诉,持续6周。使用SPSS - 16软件分析数据。
在第三、第四、第五和第六周结束时,分别有10例(11.7%)、25例(29.1%)、53例(61.6%)和28例(32.6%)患者出现皮肤并发症。在第5周和第6周,H1组并发症发生率更高(P = 0.001)。在第三、第四、第五和第六周结束时,疼痛和灼痛主诉的频率分别为15例(17.4%)、37例(43.0%)、52例(60.5%)和1例(1.2%)。H1组在第四和第五周的疼痛和灼痛强度低于α组(P = 0.010)。在第三、第四和第五周结束时,皮肤瘙痒主诉分别为16例(18.6%)、25例(29.1%)和28例(32.6%)。在这些周期间,H1%组的这种并发症较少(P < 0.05)。
α软膏在缓解疼痛和灼痛、预防除瘙痒外的并发症方面比H1%更有效。使用α软膏或将其与H1%联合使用似乎是降低放疗所致损伤和皮肤并发症发生率的合适策略。